Document Detail


Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
MedLine Citation:
PMID:  23392352     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thromboses represent a major cause of morbidity and mortality in polycythemia vera but the contributing mechanisms are not fully described. To evaluate whether environmental conditions such as altitude/hypoxia could impact thrombosis history, we retrospectively analyzed thrombosis history in 71 polycythemia vera patients living at an elevation of 5000 feet or more in the Salt Lake City (SLC) area and 166 polycythemia vera patients living near sea level in the Baltimore (BLM) area. The SLC cohort was older with a longer disease duration. No significant differences in type of anticoagulation therapy or prothrombotic factors were present between the two cohorts. After adjusting for age, sex and disease duration, SLC patients experienced an estimated 3.9-fold increase in the odds of a history of thrombosis compared with BLM patients (95% confidence interval 1.8-7.6; P=0.0004). A history of a cardiovascular event was present in 58% of the SLC patients compared with 27% of the BLM patients (P<0.0001). Before diagnosis, thrombosis occurred in 18 and 4% of the SLC and BLM groups, respectively (P=0.003). No correlation between the JAK2 allele burden and thrombosis was observed in this study. This retrospective study suggests that even moderate hypoxia associated with 5000 feet elevation should be considered as an independent prothrombotic risk factor. This observation needs to be confirmed by prospective studies.
Authors:
Maurizio Zangari; Louis Fink; Giulia Tolomelli; Jasmine C H Lee; Brady L Stein; Kimberly Hickman; Sabina Swierczek; Todd W Kelley; Tamara Berno; Alison R Moliterno; Jerry L Spivak; Victor R Gordeuk; Josef T Prchal
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  24     ISSN:  1473-5733     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-22     Completed Date:  2013-08-30     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  311-6     Citation Subset:  IM    
Affiliation:
Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Altitude
Anoxia / complications*,  genetics,  pathology
Female
Humans
Janus Kinase 2 / genetics
Male
Middle Aged
Polycythemia Vera / complications*,  genetics,  pathology
Polymorphism, Single Nucleotide
Retrospective Studies
Risk Factors
Thrombosis / complications*,  genetics,  pathology
Grant Support
ID/Acronym/Agency:
P01 CA108671/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
EC 2.7.10.2/JAK2 protein, human; EC 2.7.10.2/Janus Kinase 2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species ...
Next Document:  Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression.